Month: June 2024

  June 6, 2024Company announcement No. 20 Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the Executive Leadership Team covering the performance period 2024-2026 has been established. The program complies with the Remuneration Policy for the Executive Management and the Board of Directors of Novonesis, as approved at Novonesis Annual Shareholders’ Meeting on April 30, 2024. The LTI consists of 100% performance shares. The performance measures have 40% weight on compounded annual revenue growth, 20% weight on adjusted EBITDA, 20% weight on adjusted ROIC excluding goodwill, and 20% weight on non-financial sustainability targets. The value of the program is based on the average trading price for Novonesis B shares on Nasdaq Copenhagen during the...

SINGAPORE, June 06, 2024 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company“), is pleased to announce that the Energy Council has awarded Valeura the Upstream Company of the Year award, and has selected Dr. Sean Guest, President and CEO, as Executive of the Year. The awards were announced on June 5, 2024 at the Asia Pacific Energy Capital Assembly and Awards Dinner in Singapore, which assesses regional expertise and awards the top performers amongst the oil and gas industry within the Asia-Pacific region.  Sean Guest, President and CEO commented:“I am delighted to have our successes recognised by the Oil and Gas Council.  We strive to add value in everything we do, and being named ‘Upstream Company of the Year’ energises us to continue pursuing our...

Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for accelerated approval in MASH Denifanstat showed a statistically significant improvement in liver fibrosis ≥1-stage without worsening of MASH in the ITT population, including in patients with baseline stage 3 fibrosis Statistical significance also shown in improvement of liver fibrosis ≥2-stage without worsening of MASH in the mITT population, including in patients with baseline stage 3 fibrosis Tripalmitin, a biomarker of denifanstat activity, showed an early and sustained reduction in de novo lipogenesis at 4-weeks Safety in the ITT population showed denifanstat was generally well tolerated Management to host live webcast with Principal...

BEIJING, June 06, 2024 (GLOBE NEWSWIRE) — QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced its unaudited financial results for the third quarter of the fiscal year ending June 30, 2024 (the “third quarter of FY 2024”, which refers to the quarter from January 1, 2024 to March 31, 2024). Highlights for the Third Quarter of FY 2024Revenues for the third quarter of FY 2024 were RMB945.6 million (US$131.0 million), representing a change of 3.6% from the second quarter of the fiscal year ending June 30, 2024 (the “second quarter of FY 2024”) and an increase of 17.1% from the third quarter of the fiscal year ended June 30, 2023 (the “third quarter of FY 2023”). Gross billings of individual online learning services1 for the third quarter of FY...

PRESS RELEASE                                         Share Buyback Transaction Details May 30 – June 5, 2024 Alphen aan den Rijn – June 6, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 140,804 of its own ordinary shares in the period from May 30 2024, up to and including June 5, 2024, for €20.7 million and at an average share price of €146.81. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024 to date...

VANCOUVER, B.C., June 06, 2024 (GLOBE NEWSWIRE) — WEST MINING CORP. (“WEST” OR THE “COMPANY”) (CSE: WEST) (OTC: WESMF) (FRA: 1HL) is pleased to announce the appointment of Harrison Cookenboo, Ph.D., P.Geo., to its advisory board. Dr. Cookenboo is a professional geologist with more than 35 years of experience studying and evaluating geologic prospects, deposits and processes around the world. Dr. Cookenboo completed his B.Sc. cum laude, in geology, at Duke University, in the United States of America, and then worked for 5 years in hydrocarbon exploration in the offshore Gulf of Mexico region. He then completed both his M.Sc., and Ph.D. in geology at the University of British Columbia, in Canada. He has broad exploration and research experience in both precious and base metals, diamonds, kimberlites, as well as sedimentological processes,...

BEIJING, June 06, 2024 (GLOBE NEWSWIRE) — QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced changes in the composition of its board of directors (the “Board”) and management. The Company received a letter of resignation dated June 5, 2024 from Mr. Jinshan Li, notifying the Company of his resignation as a director effective upon June 5, 2024 and the chief technology officer effective upon June 30, 2024, for personal reasons not resulting from any disagreement with the Company on any matter relating to the Company’s operations, policies or practice. Mr. Jinshan Li has been a valued member of the executive team and has contributed significantly to the Company’s achievements during his tenure. The decision to resign comes after Mr. Jinshan Li...

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1μL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2μL of sample. This represents a powerful new...